Alto Neuroscience, Inc. (NYSE:ANRO) Receives Consensus Rating of “Buy” from Analysts

Shares of Alto Neuroscience, Inc. (NYSE:ANRO) have received a consensus recommendation of “Buy” from the seven ratings firms that are presently covering the firm, MarketBeat.com reports. Seven research analysts have rated the stock with a buy rating. The average 1 year target price among analysts that have issued ratings on the stock in the last year is $33.80.

Several research analysts recently issued reports on the stock. Rodman & Renshaw assumed coverage on shares of Alto Neuroscience in a research note on Friday, June 21st. They set a “buy” rating and a $43.00 target price on the stock. Wedbush reissued an “outperform” rating and set a $29.00 price objective on shares of Alto Neuroscience in a research report on Tuesday, September 10th. Finally, William Blair reaffirmed an “outperform” rating on shares of Alto Neuroscience in a research report on Tuesday, September 10th.

Insider Activity

In related news, insider Adam Savitz bought 12,069 shares of the company’s stock in a transaction dated Tuesday, July 9th. The shares were bought at an average price of $12.60 per share, for a total transaction of $152,069.40. Following the completion of the acquisition, the insider now directly owns 36,920 shares of the company’s stock, valued at $465,192. This trade represents a 0.00 % increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through this link.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in the company. RA Capital Management L.P. purchased a new stake in shares of Alto Neuroscience during the first quarter valued at approximately $21,267,000. Price T Rowe Associates Inc. MD bought a new stake in Alto Neuroscience in the first quarter worth about $9,788,000. Vanguard Group Inc. purchased a new position in Alto Neuroscience in the first quarter valued at about $8,233,000. Jennison Associates LLC bought a new position in shares of Alto Neuroscience during the 1st quarter valued at approximately $7,039,000. Finally, Artal Group S.A. bought a new position in Alto Neuroscience during the first quarter valued at $5,372,000.

Alto Neuroscience Stock Up 2.6 %

Shares of Alto Neuroscience stock opened at $10.45 on Friday. The business has a 50-day moving average price of $11.53 and a two-hundred day moving average price of $12.74. Alto Neuroscience has a 1-year low of $7.91 and a 1-year high of $24.00. The company has a current ratio of 19.85, a quick ratio of 19.85 and a debt-to-equity ratio of 0.04.

Alto Neuroscience (NYSE:ANRO) last issued its earnings results on Tuesday, August 13th. The company reported ($0.60) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.67) by $0.07. As a group, sell-side analysts expect that Alto Neuroscience will post -2.63 earnings per share for the current year.

About Alto Neuroscience

Alto Neuroscience, Inc operates as a clinical-stage biopharmaceutical company in the United States. Its product pipeline comprising ALTO-100, which is in phase 2b clinical trial for the treatment of patients with major depressive disorder (MDD); and which is in phase 2a clinical trial for the treatment of post-traumatic stress disorder.